По вашему запросу найдено документов: 913

Страница 31 из 92

Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Oza, Amit M, Lisyanskaya, Alla, Fedenko, Alexander, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Kristeleit, Rebecca (2025)
. Patients were randomly assigned (2:1) using an interactive response technology and block randomisation
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca, Lisyanskaya, Alla, Fedenko, Alexander, Dvorkin, Mikhail, de Melo, Andreia Cristina, Shparyk, Yaroslav, Rakhmatullina, Irina, Bondarenko, Igor, Colombo, Nicoletta, Svintsitskiy, Valentyn, Biela, Luciano, Nechaeva, Marina, Lorusso, Domenica, Scambia, Giovanni, Cibula, David, Póka, Róbert, Oaknin, Ana, Safra, Tamar, Mackowiak-Matejczyk, Beata, Ma, Ling, Thomas, Daleen, Lin, Kevin K, McLachlan, Karen, Goble, Sandra, Oza, Amit M (2022)
patients were randomly assigned (2:1), using an interactive response technology and block randomisation
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Onorato, Eustaquio Maria, Onorato, Eustaquio Maria, Muratori, Manuela, Smolka, Grzegorz, Wojakowski, Wojtek, Pysz, Piotr, Zorinas, Aleksejus, Zakarkaite, Diana, Eltchaninoff, Hélène, Litzer, Pierre-Yves, Godart, François, Calvert, Patrick, Christou, Christos, Mussayev, Abdurashid, Missiroli, Bindo, Buzaev, Igor, Curello, Salvatore, Tesorio, Tullio, Bartorelli, Antonio Luca (2022)
with the Occlutech Paravalvular Leak Device (PLD) showed long-lasting improvements in clinical parameters, including
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
Context: Somatrogon is a long-acting recombinant human growth hormone (rhGH) in development
Использование комбинации бевацизумаб + интерферон α-2А у больных диссеминированным раком почки в сравнении с группой активного наблюдения
Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group
К. Ш. Ганцев, K. Sh. Gantsev, А. А. Хмелевский, A. A. Khmelevskiy (Креативная хирургия и онкология, №4, 2019)
THE ROLE OF SMALL INTESTINE LENGTH IN THE DEVELOPMENT OF SHORT BOWEL SYNDROME
Хасанов, Р. Р., Гумеров, А.А., Вессель, Л.М., Khasanov, R.R., Gumerov, A.A., Vessel, L.M. (2017)
ranged from 5 to 55 cm (11.8±5.59% from normal length for certain age).Described small bowel length has
QUANTITATIVE ANALYSIS OF STRUCTURE−ACTIVITY RELATIONSHIPS OF TETRAHYDRO2HISOINDOLE CYCLOOXYGENASE2 INHIBITORS
Khayrullina, V.R., Gerchikov, A.Ya., Lagunin, A.A., Zarudii, F.S. (2015)
Hisoindole, 2,3dihydro1H pyrrolyzine, and benzothiophene in the concentration range of 0.6700 nmol/liter IC50
SIMPLE MORTALITY PROGNOSTIC RISK CALCULATOR FOR PATIENTS WITH ACUTE CORONARY SYNDROME
Zagidullin, N., Travnikova, E., Zagidullin, B., Zulkarneev, R., Zagidullin, S. (2016)
was the mortality risk ranging from 0 to 1 (min-max). The program was tested in 50 patients with ACS (25 non- and 25
QSAR MODELLING OF THYMIDYLATE SYNTHASE INHIBITORS IN A SERIES OF QUINAZOLINE DERIVATIVES
Khairullina, V.R., Gerchikov, A.Ya., Lagunin, A.A., Zarudii, F.S. (2017)
range 0.52 – 24,800.00 nM. Statistically significant QSAR models were constructed using MNA- and QNA
CLINICAL FORMS OF HUNTINGTON’S DISEASE IN THE PATIENTS FROM REPUBLIC OF BASHKORTOSTAN
Magzhanov, R., Saifullina, E. (2014)
-rigid form were often observed in Bashkir families with HD (motor age of onset ranged from 27 to 32 years

Страница 31 из 92

Google Scholar
OpenDoar

Фасеты

Научный руководитель
Авторы
Ключевые слова
Год